Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Is it okay to take anti histamine when on statins?
Brenzavvy discontinuation?
Is guselkumab off patent in u s?
Dabrafenib and trametinib price?
When oxcarbazepine patent expired?

Ocrevus price in europe?

See the DrugPatentWatch profile for Ocrevus

Ocrevus is a medication used to treat relapsing and progressive forms of multiple sclerosis. In Europe, the price of Ocrevus can vary significantly by country due to different healthcare systems, pricing regulations, and negotiated rebates.

How much does Ocrevus cost in specific European countries?


Exact pricing for Ocrevus in Europe is not publicly available in a consolidated format. Pharmaceutical companies typically negotiate prices directly with national health authorities. Factors influencing these negotiations include the drug's clinical effectiveness, its impact on patient quality of life, and the overall budget of the healthcare system. For precise cost information in a particular European country, consultation with local healthcare providers or national health agencies would be necessary.

When is Ocrevus patent protection expected to end in Europe?


Patent expiry dates determine when generic or biosimilar versions of a drug can enter the market, potentially lowering prices. For Ocrevus (ocrelizumab), patent information is complex and can involve multiple patents covering the drug itself, its manufacturing processes, and its uses. DrugPatentWatch.com tracks these patents and their expiration timelines. Specific European patent expiries for Ocrevus would need to be checked through specialized patent databases, as these dates can vary by country within Europe based on national patent filings and legal challenges. [1]

What are the treatment costs associated with Ocrevus?


Beyond the direct drug price, the total cost of Ocrevus treatment includes administration fees, as it is an intravenous infusion, as well as costs for monitoring, physician visits, and potential management of side effects. These associated costs are also subject to the healthcare system and insurance coverage within each European nation.

Are there any Ocrevus alternatives available in Europe?


Multiple sclerosis treatments available in Europe include other disease-modifying therapies, such as interferon beta, glatiramer acetate, fingolimod, teriflunomide, and natalizumab. The choice of treatment depends on the specific type and progression of MS, as well as individual patient factors and physician recommendations. These alternatives also have their own pricing structures and patent situations.

Who manufactures Ocrevus?


Ocrevus is manufactured by Genentech, a member of the Roche Group. [2]

What is the typical dosage and administration of Ocrevus?


Ocrevus is administered via intravenous infusion. The typical dosing regimen for relapsing forms of MS involves infusions every six months. For primary progressive MS, the same dosing schedule is followed. [3]

---

Sources:

1. DrugPatentWatch.com
2. "Ocrevus (ocrelizumab)." Genentech. Accessed [Date].
3. "Ocrevus Prescribing Information." Genentech. Accessed [Date].



Other Questions About Ocrevus :

Ocrevus zunovo vs ocrevus? Ocrevus loe? Can ocrevus be used for primary progressive multiple sclerosis? Ocrevus ocrelizumab patent expiration 2029 roche loss exclusivity? Why is ocrevus so expensive? Ocrevus revenue? What patents cover ocrevus's formula?

AI-Drug Label Prescribing Information Alignment Report

90
90%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

All OCREVUS clinical use and administration claims are consistent with the provided FDA label excerpts (Sections 1 and 2). Non-label company/manufacturing affiliation statements are not contradicted by the provided label excerpts but are not verifiable from them.

Category Scores

Indication
100
Excellent
Dosage
95
Excellent
Indication
100
Excellent

Accurate Statements

Ocrevus (ocrelizumab) is used to treat relapsing forms of multiple sclerosis.
Section 1 INDICATIONS AND USAGE: “Relapsing forms of multiple sclerosis (MS) … in adults”
Ocrevus (ocrelizumab) is used to treat progressive forms of multiple sclerosis.
Section 1 INDICATIONS AND USAGE: “Primary progressive MS, in adults” (progressive form covered by label excerpt as primary progressive MS).
Ocrevus is administered via intravenous infusion.
Section 2.3 DOSAGE AND ADMINISTRATION: “OCREVUS is administered as an intravenous infusion.”
For relapsing forms of multiple sclerosis, Ocrevus is given in a dosing regimen of infusions every six months.
Section 2.3: “Subsequent doses are administered every 6 months thereafter (see Table 1).”
For primary progressive multiple sclerosis, Ocrevus is given on the same dosing schedule of infusions every six months.
Section 2.3: “Subsequent doses are administered every 6 months thereafter (see Table 1).” (Label excerpt does not distinguish schedule by indication beyond IV infusion regimen framing.)

Unsupported Statements

Ocrevus is manufactured by Genentech.
Company/manufacturing information is not included in the provided FDA label excerpts, so support cannot be verified from the supplied text.
Genentech is a member of the Roche Group.
Corporate affiliation is not included in the provided FDA label excerpts, so support cannot be verified from the supplied text.

Contradictions

Important Omissions

The dosing schedule includes an initial dose split into two equal infusions administered two weeks apart before the every-6-month maintenance dosing (for the claimed every-six-month regimen).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The claims evaluated are largely on-label regarding indications and IV administration. The only material nuance omitted is the initial two-week split-dosing detail; no safety contraindication or warning claims were made.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Maintenance dosing was stated without the label-specified initial two-week split dosing detail.

Suggested Improvement
Qualify the regimen by stating that the initial dose is split into two equal IV infusions administered two weeks apart, followed by subsequent doses every 6 months.

Drug Brand Mention Assessment

Branding Score
44
Visibility
52
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

medication used to treat relapsing and progressive forms of multiple sclerosis

Core Claims
  • Ocrevus is used to treat relapsing and progressive multiple sclerosis.
  • In Europe, the price of Ocrevus varies significantly by country.
  • Exact pricing is not publicly available in a consolidated format.
  • Total treatment cost includes administration fees and monitoring/visit/side-effect costs.
  • Ocrevus is manufactured by Genentech (member of the Roche Group).
Differentiators
  • Pricing varies by country due to healthcare systems, regulations, and negotiated rebates.
  • Total cost includes infusion administration and related healthcare costs beyond the drug price.
  • Patent timelines may affect pricing via potential generic/biosimilar entry.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Genentech 35%
50 #2 No
Roche 35%
50 #2 No